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ADIPOQ and adiponectin: the 
common ground of hyperglycemia 
and coronary artery disease? 
ADIPOQ e adiponectina: base comum da 
hiperglicemia e doença arterial coronariana?
Carolina S. V. Oliveira1, Fernando M. A. Giuffrida1, Felipe Crispim1,  
Pedro Saddi-Rosa1, André Fernandes Reis1
SUMMARY
Plasma adiponectin and the coding gene for adiponectin, ADIPOQ, are thought to explain part 
of the interaction between obesity, insulin resistance, type 2 diabetes (T2DM) and coronary 
artery disease (CAD). Here, we illustrate the role that adiponectin and ADIPOQ variants might 
play in the modulation of CAD, especially in the occurrence of hyperglycemia. Recent evidence 
suggests that total and high molecular weight (HMW) adiponectin levels are apparent markers 
of better cardiovascular prognosis in patients with low risk of CAD. However, in subjects with 
established or high risk of CAD, these levels are associated with poorer prognosis. We also 
provide recent evidences relating to the genetic control of total and HMW adiponectin levels, 
especially evidence regarding ADIPOQ. Accumulated data suggest that both adiponectin levels 
and polymorphisms in the ADIPOQ gene are linked to the risk of CAD in patients with hypergly-
cemia, and that these associations seem to be independent from each other, even if adiponec-
tin levels are partly dependent on ADIPOQ. Arq Bras Endocrinol Metab. 2011;55(7):446-54
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SUMáRio
Os níveis plasmáticos de adiponectina e o gene codante desta proteína, ADIPOQ, parecem 
explicar parte da interação de doenças como obesidade, resistência à insulina, diabetes melito 
tipo 2 (DM2) e doença arterial coronariana (DAC). Apresentamos as evidências do papel tanto 
dos níveis de adiponectina quanto das variantes no ADIPOQ na modulação da DAC, sobretudo 
na presença de hiperglicemia. Estudos recentes sugerem que níveis de adiponectina total e de 
alto peso molecular (HMW) são marcadores de bom prognóstico DAC, sobretudo em pacientes 
de baixo risco cardiovascular, enquanto nos pacientes de alto risco ou com doença já estabe-
lecida podem se associar com pior prognóstico. Apresentamos também as evidências em rela-
ção ao possível controle genético dos níveis circulantes de adiponectina, tanto total quanto da 
isoforma de alto peso molecular, sobretudo em relação ao ADIPOQ. A análise global dos dados 
sugere que tanto os níveis circulantes de adiponectina quanto polimorfismos no gene ADIPOQ 
estão implicados na evolução de DAC em pacientes com hiperglicemia e que essas associações 
podem existir de forma independente. Arq Bras Endocrinol Metab. 2011;55(7):446-54
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iNTRoDUCTioN
ardiovascular disease (CVD) is the leading cause 
of mortality and morbidity in patients with type 2 
diabetes mellitus (T2DM) and accounts for up to 80% 
of deaths in patients with this disorder (1). It is be-
lieved that diabetic patients have a 3-fold higher risk 
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than nondiabetic individuals of developing atheroscle-
rosis and its clinical complications, such as peripheral 
vascular disease, coronary artery disease (CAD) and 
stroke (1,2). Classical risk factors for atherosclerosis, 
such as central obesity, arterial hypertension, and dys-
lipidemia, frequently coexist with diabetes and con-
tribute to the increased prevalence of CAD. However, 
T2DM remains an independent risk factor for CVD, 
even after adjustment for these comorbid conditions 
(1,3). The mechanistic links between T2DM and ath-
erosclerosis remain largely unclear, but several meta-
bolic dysfunctions associated with T2DM have been 
proposed to contribute to the acceleration of athero-
sclerosis (3). In this context, proteins, mainly those 
secreted by adipose tissue, known as adipokines (for 
example: adiponectin, leptin, resistin and visfatin/
Nampt) and other known secretory products of adi-
pose tissue, could play a role in the interaction of com-
plex diseases and traits such as obesity, insulin resis-
tance, T2DM and CVD (4-6).
Similar to many other highly prevalent diseases, 
T2DM and CVD are believed to be multifactorial and 
determined by interactions among numerous environ-
mental factors and predisposing genes. Genome-wide 
associations studies (GWAS) have identified genes that 
influence the risk of developing both CVD and T2DM 
(7). The candidate gene approach has also revealed that 
variants of some genes that are involved in the patho-
physiology T2DM and CVD are actually associated with 
the prevalence and incidence of these diseases (1,7).
Given that the function of adiponectin apparently 
modulates the pathophysiology of both T2DM and 
CVD (5), the coding gene ADIPOQ is a good can-
didate gene that could determine concomitant risk to 
both diseases (8). The investigation of this hypothesis 
has generated positive results, as will be discussed in this 
review. In addition, the area of the genome that harbors 
ADIPOQ has been identified by GWAS to be a sus-
ceptibility locus for risk of metabolic syndrome, T2DM 
and CVD (2). Studies have shown that ADIPOQ has 
some influence on adiponectin levels and plasma iso-
form levels, which are themselves related to modulation 
of the risk of developing T2DM and CVD (9). 
The aim of this review was to provide an update 
about the role of the ADIPOQ as an independent de-
terminant of CVD, particularly in the occurrence of 
hyperglycemia. In addition, we discuss recent evidence 
on the genetic modulation of both total and high mo-
lecular weight (HMW) adiponectin levels. 
PLASMA ADiPoNECTiN AS A CARDioMETABoLiC 
MARKER
Experimental data suggest that adiponectin exerts a di-
rect protective effect on the vessels, probably due to its 
anti-inflammatory and anti-atherosclerotic properties, 
having multiple favorable effects on glucose and lipid 
metabolism (2-5,7). Epidemiological studies demon-
strate an association between lower adiponectin and 
the prevalence and incidence of insulin resistance, and 
T2DM in various populations (10). There are indica-
tions that this progression to diabetes associated with 
low adiponectin levels is modulated by insulin resis-
tance (11,12). A recent meta-analysis emphasized the 
substantial inverse association between total plasma 
adiponectin levels and the incidence of T2DM, which 
was clearly consistent in various populations (10).
Adiponectin has a seemingly salutary influence on 
some phenotypes clearly associated with CVD, such 
as blood pressure, inflammation, lipid profile and en-
dothelial dysfunction (5). Independent of its influence 
in these traditional risk factors, several cross-sectional 
studies of diverse populations have documented an in-
verse association between lower plasma levels of total 
adiponectin and higher prevalence of CAD (13-17). 
However, other cross-sectional analyses found no asso-
ciation between total adiponectin levels and the preva-
lence of CAD (18,19,21).
In addition to the cross-sectionals surveys, some 
large prospective studies evaluated the association be-
tween adiponectin levels and incident CAD. Several of 
these studies indicate an inverse correlation between 
adiponectin and CVD incidence (Table 1). For in-
stance, a nested case-control study of Caucasian Amer-
ican men (7% T2DM) documented that higher total 
adiponectin levels were protective for incident CAD 
(14). Results were maintained in the posterior analy-
sis of the diabetic subgroup (20). Another example of 
an inverse correlation between  adiponectin and inci-
dent CAD is the study of older (mean age, 70 years 
old) Swedish Caucasians (~8% T2DM) in which base-
line concentrations of adiponectin were negatively as-
sociated with CAD development (18). In a group of 
Caucasian Dutch women without prevalent CAD at 
baseline, a higher total adiponectin level was protec-
tive against the development of CAD, even after adjust-
ment for the presence of T2DM (22). However, in the 
same study, the analysis that included all patients with 
CAD at baseline found that higher total adiponectin 
Adiponectin and cardiovascular disease
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levels were associated with higher mortality. In an older 
Caucasian Californian population (15% T2DM) (19), 
male subjects with higher total adiponectin levels were 
protected from nonfatal CAD, but higher total adipo-
nectin was associated with increased mortality risk. Re-
sults were adjusted for glucose levels. A similar result 
was observed for a European population (31% T2DM) 
followed up for 5.4 years (15). In this cohort, higher 
total adiponectin was associated with higher mortality, 
but this association was not significant in the group that 
was CAD negative at baseline, even after adjustment 
for T2DM. Two other studies demonstrated the as-
sociation of higher total adiponectin levels with worse 
cardiovascular outcomes in Americans (15% T2DM) 
(21) and Germans (85%T2DM) (23). However, there 
are several studies that demonstrated a neutral effect of 
adiponectin levels on the risk of incident CAD disease. 
This neutral effect was noted in several populations 
with different percentages of diabetic patients (15%-
75%) among studied patients (13,16,24). Differences 
in population characteristics, statistical adjustments 
(especially for the presence of diabetes) and statistical 
power, or even analytical methods, might explain part 
of the apparent discrepancies between studies. 
Altogether, accumulated evidence suggests that 
higher plasma adiponectin is a surrogate biological 
marker for better cardiovascular prognosis, mainly in pa-
tients with low risk of CVD. In subjects with high risk 
of CVD, or in those with established CAD, however, 
higher total adiponectin level seems to be associated 
with poorer prognosis (25). A possible explanation is 
that higher levels of adiponectin may be a physiological 
response to limit endothelial damage in the very early 
stage of the atherogenic process. In more advanced dis-
ease, however, the compensatory processes, including an 
increase in adiponectin levels, are often surpassed (25). 
Additionally, the finding of negative associations may be 
partly due to the preferential measurement of total adi-
ponectin in the majority of these investigations (26-31).
Are adiponectin isoforms better cardiometabolic 
markers?
As mentioned above, one of the current hypotheses for 
the lack of consistent association between adiponectin 
and better overall and cardiovascular outcomes is that 
risk is more influenced by isoform distribution than by 
total adiponectin levels. Adiponectin is present in plas-
ma in at least three homomeric complexes/isoforms, 
trimer, hexamer (trimer–dimer) and ‘‘high molecular 
weight’’ HMW. There is growing interest in the role of 
these isoforms in metabolism and disease, as research 
suggests that oligomeric state affects the biological ac-
tivity of adiponectin (26). Lower HMW adiponectin 
levels have been associated with more prevalent T2DM 
in Japanese and Italian cohorts, and with a higher inci-
dence of T2DM in an American cohort (26). 
The epidemiological evidence of an association be-
tween adiponectin isoforms and CVD is still scarce and 
mostly based on the HMW isoform. A cross-sectional 
study that evaluated diabetic Japanese subjects demon-
strated that lower HMW adiponectin levels were associ-
ated with higher prevalence of DAC (27). Severity of 
CAD risk was inversely associated with HMW adiponec-
tin levels in a German population (17% T2DM) (28). 
In a Japanese cohort of subjects at higher risk of CVD 
(40% T2DM), HMW adiponectin was lower in more 
severe multi-vessel disease, and predicted future events 
after a follow-up of 7 years (29). However, HMW-ad-
iponectin levels showed no association with secondary 
cardiovascular events in prospective studies in an Euro-
pean population (17%T2DM) (28), and in one Japanese 
cohort of subjects with T2DM (31) (Table 1). 
Based on current evidence, it is still difficult to as-
certain that plasma HMW adiponectin is a better cardi-
ometabolic marker than total adiponectin levels. Addi-
tional prospective studies with rigorous adjustments for 
the traditional cardiovascular risk factors are required 
to better answer this question. 
GENETiCS oF ADiPoNECTiN LEVELS 
Considering that adiponectin levels are highly heritable 
(30%-70%), extensive research has been undertaken in 
the past few years to pinpoint which genes influence 
these levels, including ADIPOQ (2,5,32,33). Rich-
ards and cols. performed a genome-wide association 
study (GWAS) utilizing information on population-
based European cohorts (total of 14,733 subjects) to 
identify genetic variants influencing total adiponectin 
levels, and found 4 single nucleotide polymorphisms 
(SNPs) at the ADIPOQ locus that demonstrated sig-
nificant associations (34). Another combined analy-
sis of GWA studies in a healthy, Caucasian Austrian 
population (n = 4,659) singled out the ADIPOQ gene 
region as the only genome-wide significant locus for 
plasma total adiponectin. In this study, intronic SNP 
rs17366568 (-8-387G>A) showed the strongest as-
sociation and explained 3.8% of the variance in total 
adiponectin levels (35).
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Table 1. Prospective studies evaluating the risk of CAD according to total and HMW adiponectin levels
Study Population T2DM Cases Controls Baseline Follow-up
Pischon e cols.14
Schulze e cols.20
North American, 
men, 94% white
7%
100%
266
89
532
656
Lower Adn in cases
No association 
6y
6y
Higher Adn protective 
Higher Adn protective 
Frystyk e cols.18 Swedish, white, 
older men
8.5% 116 716 No association after adjusting 
HDL
8y Higher Adn protective 
Dekker e cols.22 Dutch, white, 
46% men
? Quartiles of Adn 
1248 probands
No association
better CAD risk profile
15y In women (no CAD at baseline): 
higher Adn protective 
Higher Adn: higher mortality in men: 
higher Adn less nonfatal CAD 
Laughlin e cols.19 North American, 
white 
55% men, older
15% 252 1100 Highest Adn quintile lower 
CAD 
No association after 
adjustment for HDL, Tg or 
metabolic syndrome)
20y No association in women or fatal 
CAD higher Adn: higher mortality
Pilz e cols.15 European, white
52%-75% men
31% Quartiles of Adn
3146 probands
Lower Adn in cases 5y Higher Adn: higher mortality 
not significant if CAD negative at 
baseline
Kizer e cols.21 North American
20%-60% white, 
47% men
15% 604 782 No association 4y Highest quintile more CAD, 
especially nonfatal MI and fatal CAD
Schnabel e cols.23 German, white, 
79% men high 
risk
85% 760 1130 Similar in SAP or ACS 20y Upper quartiles of Adn: highest 
event-rates 
Sattar e cols.13 Men, British, 
white
2% 589 1278 No association 16y no association 
Maiolino e cols.16 Italian, white, 
72% men
high CV risk
16% Low vs. high Adn Lower Adn association with 
atherosclerosis 
4y no association 
Luc e cols.24 European, white, 
men
4% 617 1215 No association with CAD at 
baseline
10y no association 
Inoue e cols.29 Japanese, 70% 
men
40% 124 45 HMW-Adn lower in CAD and 
multivessel
7y Higher HMW-Adn protective 
Von Eynatten e cols. 28 German, white, 
85% men
CHD patients
17% 95 956 Total and HMW associated to 
HDL-col, LDL-col and 
NT-proBNP
4.5y No association of HMW-Adn
Krzyzanowska e cols.31 Japanese, 57% 
men
100% 61 86 No association with prevalent 
CVD
1.5y No association of HMW-Adn
Adn: adiponectin; Controls: no incident or re-incident CAD; Cases: incident or re-incident CAD; ACS: acute coronary syndrome; SA: Stable angina.
The candidate gene approach has also corroborated 
the association of ADIPOQ gene SNPs and adiponec-
tin levels. The SNPs most consistently associated with 
total adiponectin levels are the variants −11391 G/A 
(rs17300539) and −11377 C/G (rs266729) located 
in the promoter region, the synonymous +45 T/G 
(rs2241766) variant located in exon 2, the +276 G/T 
(rs1501299) SNP located in intron 2, and the +2019 
single nucleotide insertion/deletion polymorphism in 
the 3´untranslated region (9). However, these are not 
the only SNPs identified by association studies. For ex-
ample, Cohen and cols. (36) studied a total of 71 SNPs 
in ADIPOQ, and adiponectin-receptor genes in multi-
ethnic women (n = 1,967). The same SNP rs17366568 
identified by Heid and cols. (see above) was the only 
one significantly associated with serum total adiponectin 
levels, although only in Caucasian women. 
Knowledge about the genetic determinants of adi-
ponectin isoform levels, on the other hand, is still scar-
ce. Menzaghi and cols. studied a family-based sample of 
640 nondiabetic white Caucasians from Italy, and sho-
wed that all adiponectin isoforms are highly heritable. 
In addition, this study reported that the association of 
rs17300539 and rs1501299 with adiponectin levels is 
due exclusively to an effect on the HMW isoform (37).
Melistas and cols., studying 349 women without 
diabetes, found that carriers of the most common 
+45T/+276G (rs2241766/rs1501299) haplotype had 
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significantly lower total adiponectin levels than non-
-carriers, even though single SNP analysis had shown 
no significant associations with circulating adiponectin 
concentrations. A similar trend was observed for HMW 
adiponectin, albeit not statistically significant (38).
ALLELiC VARiATioNS iN ADIPOQ AND CVD
Genetic factors that influence plasma levels and func-
tion of adiponectin are good candidates to account for 
part of the predisposition to atherosclerosis, especially 
in diabetic patients (1,3). Interestingly, in some re-
ports, these allelic associations were independent from 
circulating levels of adiponectin (2,7).
 The region of the genome that harbors ADIPOQ 
has been identified by GWAS and by family-based studies 
to be a susceptibility locus for the risk for the metabolic 
syndrome, T2DM and CVD (32,39). Furthermore, 
association studies also corroborate that ADIPOQ 
variants, individually or as haplotypes, are linked to 
phenotypes such as obesity, high blood pressure, 
dyslipidemia, T2DM and CVD (8,32,38,40,42,43). 
Of interest is the fact that the vast majority of 
ADIPOQ SNPs that have been implicated in these 
phenotypes are either located in non-coding regions 
or are synonymous variants, and that the variants 
associated with alterations in adiponectin levels are 
not consistently associated with CVD risk. Therefore, 
the causative role these SNPs play in influencing CVD 
might be due to a direct effect on adiponectin levels, but 
more probably by modulation in other systems directly 
or indirectly involved in CVD in diabetic subjects (37). 
There are three SNPs in ADIPOQ that have 
been more extensively studied and show more con-
sistent evidence of association with CAD: rs266729 
(-11377C>G), rs2241766 (+45T>G), and rs1501299 
(+276G>T). For that reason, they will be approached 
separately in the following section (Figure 1).
rs266729 (-11377C>G)
SNP rs266729 is located in the promoter region of ADI-
POQ, in the first linkage disequilibrium (LD) block, 
and consists of a C>G substitution in the -11377 posi-
tion (or -11365, depending on the reference sequence 
employed). This SNP is in LD with other two polymor-
phisms in the promoter region (rs16861194 [-11426 
A/G] and rs17300539 [-11391 A/G]), and their hap-
lotypes seems to affect promoter activity (39). In cohorts 
of 162 French and Swiss type 2 diabetic patients and 315 
normal controls, Lacquemant and cols. found no associa-
tion between CVD and rs266729, individually. However, 
haplotype analyses showed the combination of five SNPs 
in wild-type alleles (rs266729 -11377C>G, -4041A>C, 
rs2241766 +45T>G, rs1501299 +276G>T, +349A>G, 
+2019delA) in the decrease in CAD risk, even after ad-
justment (OR: 0.5; 95% CI: 0.3–0.7; p= 0.0006) (40).
Qi and cols. (42) studied 239 CVD cases in diabetic 
American men (defined as new cases of fatal and nonfa-
tal CAD, and fatal and nonfatal stroke) and 640 control 
subjects. No association between -11377C>G (termed 
-11365C>G in this study) with CVD was observed, 
either alone or in haplotype analyses. The addition of 
plasma adiponectin, lipids, and inflammatory markers 
to the model did not appreciably change the results, and 
similar association was observed if the outcome was re-
stricted to CAD, excluding the stroke cases. Soon after 
that, the same authors published their investigation of 
associations between these SNPs and adiponectin levels 
and CVD risk in a cohort of American diabetic women 
including 285 cases and 704 controls (43). Those GG 
homozygotes in rs266729 had significantly decreased 
plasma total adiponectin levels,  compared with C-al-
lele carriers, but no association with CVD was demon-
strated. In a nested case-control of Caucasian American 
men, rs266729 polymorphism was not associated with 
the incidence of MI, although the minor allele was as-
sociated with lower incidence of stroke (44), even after 
adjustment for the presence of T2DM (5% of subjects). 
Pischon and cols. (45) analyzed rs266729 in two paral-
lel studies of American men and women (on the whole, 
8.4% subjects with T2DM). The major C-allele SNP 
rs266729 was associated with an increased number of 
coronary artery bypass grafts (CABG) or percutaneous 
transluminal coronary angioplasties (PTCA), only in 
men, even after adjustment for T2DM. Also in 2007, 
Gable and cols. (46) published data on the prospective 
risk of T2DM and CAD in a Caucasian European pop-
ulation, and found that the minor G allele of rs266729 
was associated to an increased risk of MI, but not with 
an increased risk of T2DM. Chiodini and cols. (47) 
found no association between rs266729 and the risk 
of myocardial infarction (MI) and T2DM in 2008 Ital-
ian subjects. Persson and cols. (17) studied 244 pairs 
of Swedish young survivors of MI (age < 60 years old; 
10% T2DM) and age-matched normal controls. The 
minor G allele of rs266729 was associated with lower 
total adiponectin levels, but not with MI. 
Adiponectin and cardiovascular disease
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Exon 1 Exon 2 Exon 3Intron 1 Intron 2
rs2241766 (+45T >G)
prevalence: neutral 41,49, higher 40,48
incidence: neutral 22-24, 42-46,47
rs1501299 (+276G>T)
prevalence: neutral17,40,41, lower 49
incidence: lower 42,43,47, neutral 22-24,44,45,46
rs266729 (-11377C>G, 11365 C>G)
prevalence: neutral 17,40,49
incidence: neutral 42-45, higher 46-47
• rs822395 (-4041A>C, -4034 A>C)
prevalence: neutral 40
incidence : neutral 42, higher 43,45
•rs822396 (-3964A>G, -3971A>G)
incidence: neutral 42-45
delA+2019
prevalence: neutral 40
BLOCK 1 BLOCK 2
rs2241767 (+349A>G)
prevalence: higher50
5´ 3´
•rs17300539 (11391G>A)
incidence: neutral 47 , higher 46
(-11426A>G) -32T>C
-11156insCA
-11043C>T
+712G>A
Figure 1. Variants of ADIPOQ associated with CAD.
Illustration of the ADIPOQ gene comprising 3 exons and 2 introns, focusing on SNPs associated with CAD described in the text, and their relative positions in regard to the two linkage disequilibrium 
blocks. The associations that refer to the allele are in bold type. The percentage of diabetic patients in each study is described in the text. Two notations are given for  rs266729, rs822395 and rs822396 
because they have been thus described in the literature.
Therefore, based on current published evidence, 
we concluded that the effect rs266729 might have in 
modulating CAD disease risk is limited or slightly pro-
tective, even in T2DM subjects.
rs2241766 (+45T>G)
Among the several common genetic variations of the 
ADIPOQ gene, the rs2241766 in exon 2 has been one 
of the most extensively studied. This +45T >G base 
change is a synonymous mutation (GGT → GGG, Gly 
→ Gly), although higher mRNA expression in adipo-
se tissue and higher circulating total adiponectin levels 
have been observed in G-allele carriers. Besides this po-
tential biological basis for the protective effect of this 
silent variant, it is located in the second LD block of 
ADIPOQ and might possibly be in LD with the func-
tional and causal polymorphism (32). 
A positive association between the major T allele of 
rs2241766 and CAD was observed in the two cohorts 
of French and Swiss T2DM patients described above 
(40), with OR of 2.0 (95% CI: 1.3-3.2; p = 0.02), and 
this association was independent of other traditional risk 
factors. No association was observed individually with 
the other SNPs studied. A similar result was observed 
for Chinese subjects diagnosed with CAD by coronary 
angiography (600 patients), compared with 718 non-
CAD controls (48). The minor G rs2241766 allele had 
a protective association with CAD, with an OR 0.75 
for each copy, after adjustment for classical risk factors 
not including diabetes, only adjusted for glucose levels. 
Moreover, there was an interaction between this SNP 
and blood pressure and total cholesterol levels. Many 
other studies found no association between rs2241766 
variation and CAD across various populations includ-
ing different percentages of diabetic subjects (22-24).
Taken together, these studies suggest that the 
rs2241766 has either no influence on CAD risk or con-
fers greater risk of CAD in some populations.
rs1501299 (+276G>T)
This intronic SNP is unlikely to be itself the functional 
variant and it is most probably a marker in LD with 
another functional SNP (32). Lacquemant and cols. 
found a protective association between +276G>T and 
CAD only in haplotype analyses, as described above 
(40).
Bacci and cols. investigated diabetic Italian subjects. 
Cases consisted of 142 patients with CAD (previous 
myocardial infarction or stenosis > 50% at coronary an-
giography). Control subjects (n = 234) were asympto-
matic patients with negative resting or exercise ECG 
and/or coronary stenosis < 50% at angiography. A 
significant association with CAD was observed in TT 
homozygotes presenting lower risk of CAD, compared 
with carriers of other genotypes (OR of 0.13; 95% CI: 
0.037-0.46, p = 0.002, after adjusting for potential con-
founders such as age, sex, duration of diabetes, smok-
ing, HbA1c, lipid levels, systolic and diastolic blood 
pressure, antihypertensive and antidyslipidemic treat-
ments, insulin therapy, and adiponectin levels) (49).
Adiponectin and cardiovascular disease
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As described above, a large prospective cohort of 
diabetic men (42) showed a significant association be-
tween TT homozygotes and lower risk of CVD risk, 
compared with carriers of other genotypes (OR of 
0.38; 95% CI: 0.18-0.79, p = 0.009, after appropriate 
adjustments). The addition of plasma total adiponectin, 
lipids, and inflammatory markers to the model did not 
appreciably change the results, even when the outcome 
was restricted to CAD, excluding stroke cases. No asso-
ciations were observed with the other SNPs or in haplo-
type analysis. The study of diabetic women by the same 
authors (43) found that the haplotypes of 5 common 
SNPs that possessed the allele T were also associated 
with significantly lower CVD risk than the haplotype 
of wild-type alleles (OR of 0.70; 95%CI: 0.50-0.98, p 
= 0.039). Pischon and cols. demonstrated reduced risk 
of non-fatal MI or fatal CAD in male carriers of the 
T allele of rs1501299 in American men and women 
(8.4% T2DM) (45). Chiodini and cols. (47) found a 
protective effect of TT homozygosis for +276G>T on 
myocardial infarction alone (OR = 0.58, p = 0.01), 
and on MI in association with T2DM (OR = 0.55, p = 
0.006) when compared with carriers of the G allele. A 
meta-analysis of five studies performed with the results 
of rs1501299 SNP suggested that T-allele homozygo-
sity was associated with an approximate 45% reduction 
in CVD risk (43).
Therefore, the presence of the T allele of this in-
tronic SNP shows the most consistent association with 
CVD and is apparently related to a reduction in risk.
other SNPs
Many other SNPs have been studied less often. The 
diabetic patients studied by Lacquemant and cols. sho-
wed no association between -4041A>C, +349A>G, and 
+2019delA and CAD or metabolic syndrome compo-
nents (40). Chiodini and cols. (47) found no associa-
tion of rs17300539 (-11391G>A) with the risk of myo-
cardial infarction and T2DM in Italian subjects. Ohashi 
and cols. studied British women (5%T2DM) and ob-
served an increased frequency of the +517T>C (Ile-
164Thr) heterozygosity in CAD cases, compared with 
control British women (2.9% vs. 0.8%, p < 0.05) (41).
The rs822395 (-4034A>C) variant was associated 
with increased cardiovascular risk in a recessive model 
in American diabetic women (43). Also, in the female 
subgroup of American subjects, association between 
rs822395 (-4034A>C) and risk of non-fatal MI or fatal 
CAD was demonstrated (45). Moreover, GG homozy-
gosity for rs822396 (-3964A>G) was associated with 
the same outcomes (45).
Wassel and cols. (50) studied the association be-
tween 11 ADIPOQ SNPs and common and internal 
carotid intima media thickness (cIMT), and coronary 
artery calcification (CAC) in 2847 participants in the 
Multi-Ethnic Study of Atherosclerosis (MESA) (~25% 
with T2DM). In African Americans, genotypes AG/
GG of rs2241767 were associated with 36% great-
er CAC prevalence and larger common cIMT (P = 
0.0043). Genotypes AG/AA of rs1063537 were asso-
ciated with 35% greater CAC prevalence. In Hispanics, 
the AA genotype of rs11711353 presented 37% greater 
CAC prevalence compared with the GG genotype. No 
SNP was associated with subclinical CVD phenotypes 
in Chinese or Caucasian participants. 
Accumulated data suggest that genetic variants of 
the ADIPOQ might have an influence in the genetic 
predisposition to CAD in some populations. As men-
tioned above, some studies demonstrated that allele 
associations with disease phenotypes seem to be inde-
pendent of circulating levels of adiponectin, which in-
dicate an independent effect of ADIPOQ on CAD risk 
determination and evolution. Furthermore, evidence 
of the modulation on CAD risk by ADIPOQ are not 
robust and ubiquitous. Absence of consensus in the 
various studies could be, in part, due to different study 
power, design and tested outcomes, and because of ge-
netic differences in the populations studied. 
CoNCLUSioNS
The causes and mechanisms of the increased cardio-
vascular risk observed in patients with diabetes are still 
largely unexplained. The increased risk does not seem 
to be solely dependent on the effects of hyperglycemia 
on the vessels (3). It is proposed that a common genetic 
background shared by disorders of glucose homeostasis 
and atherosclerosis might heighten the risk of athero-
sclerosis, even in the absence of hyperglycemia (1,7). 
Among the candidate genes that could fit this common 
risk hypothesis is ADIPOQ. We emphasize that the 
available evidence implicates both ADIPOQ variants 
and adiponectin circulating levels in the progression 
of CAD in patients with hyperglycemia, and that these 
associations probably exist in an independent manner, 
even if part of the genetic regulation of circulating adi-
ponectin levels is determined by ADIPOQ (2,51).
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It is important to take into consideration, when an-
alyzing these studies, that adiponectin levels may reflect 
a dynamic process. Moreover, adiponectin circulates in 
a wide range of full-length and globular multimers that 
need to be properly quantified in future studies.
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